Changes in FVC in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)
K. Highland (Cleveland, Ohio, United States of America), A. Azuma (Tokyo, Japan), A. Fischer (Denver, Colorado, United States of America), M. Kuwana (Tokyo, Japan), T. Maher (London , United Kingdom), M. Mayes (Houston, Texas, United States of America), G. Raghu (Seattle, United States of America), M. Girard (Reims, France), M. Alves (Ingelheim am Rhein, Germany), M. Gahlemann (Basel , Switzerland), O. Distler (Zurich, Switzerland)
Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Highland (Cleveland, Ohio, United States of America), A. Azuma (Tokyo, Japan), A. Fischer (Denver, Colorado, United States of America), M. Kuwana (Tokyo, Japan), T. Maher (London , United Kingdom), M. Mayes (Houston, Texas, United States of America), G. Raghu (Seattle, United States of America), M. Girard (Reims, France), M. Alves (Ingelheim am Rhein, Germany), M. Gahlemann (Basel , Switzerland), O. Distler (Zurich, Switzerland). Changes in FVC in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD). 1882
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: